Catalysts

Catalysts — What Can Move the Stock

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, multiples, percentages, dates and share counts are unitless and unchanged.

The next six months hinge on two events that both fall in early July: the 6 July US NEC bellwether trial (the first verdict in the consolidated MDL on Mead Johnson's Enfamil) and the H1 2026 results around 24 July, where management has to confirm or cut the 4–5% Core LFL guide after Q1 printed +1.3%. Everything else on the calendar — AGM, Focus On Digital Science, the $727m buyback tranche completing — is secondary. The single soft window that could overshadow both is a Mead Johnson disposal headline, with Danone reportedly engaged via Centerview Partners but no transaction yet. Tape is unhelpful: fresh death cross on 16 April 2026, price 16.6% below the 200-day SMA, and realised vol back in the stressed regime — meaning even small misses can produce outsized moves.

Catalyst Setup

The calendar is busier than it looks: an early-July litigation verdict that mechanically sets the Mead Johnson disposal price, a late-July earnings print that decides whether the 4–5% guide survives, an AGM vote at the start of the window, and a continuously open Mead Johnson sale process where a disclosed buyer at a defensible price is the single largest single-day swing factor in the next 12 months. Signal quality is medium (3/5) — most dates are confirmed from primary sources, but the two highest-impact items (MJN buyer/price; NEC verdict) are intrinsically uncertain.

Ranked Catalyst Timeline

The ranking is decision-value, not chronology: H1 results displaces the Focus On event by impact magnitude even though the Focus On event arrives first. Items 1–3 are the only catalysts that can plausibly move the EV/EBITDA multiple by more than ~1 turn over the next 6 months; items 4–7 reset narrative tilt; items 8–10 are option-value or tail-risk. There is no scheduled investor day in the next 6 months — the November 2026 Focus On: North America falls outside the window.

Impact Matrix

Three of the six rows are direct bull-vs-bear resolutions (H1 results, NEC verdict, MJN disposition). The Mucinex launch is the variant-perception lever — the market currently treats Q1 Self Care -0.1% as the steady state; a strong June ramp is the cleanest data point that says price/mix engine still works on the gross line. The tape and AGM rows are implementation rather than fundamentals: they shape sizing and entry, not the thesis itself.

Next 90 Days

The next 90 days take us through 26 July 2026 and capture the highest-density catalyst window of the year:

• 14 May 2026 — Reckitt Focus On: Digital Science (virtual). Watch for named AI-tooled product launches and a quantified efficiency claim (e.g. R&D cycle time reduction). Bigger than the headline because this is the first event after Q1 where management can re-set narrative tone; absent quantification, it becomes another framework on the pile.
• 21 May 2026 — AGM, London Heathrow Marriott (2pm). The remuneration vote matters more than the headline — a sub-80% pass on rem with named opposition would change the read on the +7% Essential Home bonus adjustment and put the 2026 LTIP design on watch. Two new NEDs (Kirsch / Nath) stand for first election.
• June 2026 (window) — Mucinex 12-hour Cold & Fever ships into US retail. The first hard read on whether the innovation pipeline is real. Watch retailer sell-in commentary at H1 and the Self Care non-seasonal LFL split — sub-3% would be a yellow light on the gross-margin moat argument.
• 6 July 2026 — NEC MDL bellwether trial (N.D. Illinois). Verdict timing typically 1–4 weeks from trial start. A defence win supports the case for Danone bid at full carrying value; a $200m+ plaintiff verdict per case anchors a settlement framework in the $2.0–4.0bn zone and likely triggers an FY2026 third MJN/CGU impairment.
• ~24 July 2026 — H1 2026 results (date inferred from prior-year 24 Jul 2025 cadence; $727m buyback tranche has a 27 July deadline that confirms the window). The single highest-impact print of the next 12 months. Watch for: Group + Core LFL split, EM ex-Russia volume sign, H1 adj op margin vs guided ~22.6%, and any change in the FY 4–5% Core LFL guide language.

What Would Change the View

Three observable signals over the next six months would force the debate to update materially. First, a Core Reckitt H1 LFL print at 3% or above with positive EM ex-Russia volume and a reaffirmed FY guide — this resolves the bear's primary trigger and supports the bull's central rerating-to-peer-median thesis. Second, a verdict on the 6 July NEC bellwether trial that either (a) clears Reckitt with prejudice, removing the litigation overhang on a Mead Johnson sale at full carrying value, or (b) returns a $200m+ award per case, triggering a third MJN/CGU impairment and re-pricing any disposal at an $8bn-or-below band. Third, a disclosed Mead Johnson buyer at a defensible EV — the Danone process via Centerview Partners is the most credible pathway, but a private-equity infant-nutrition platform or partial separation would resolve the same question. Tied back to the work: signal 1 is the bear's cover trigger and the bull's multiple-gap-closer; signals 2 and 3 are the historian's "single most-watched item" finally delivering an answer. Anything else in the next 6 months — Focus On Digital Science, AGM, Mucinex launch, Russia, the SDNY motion-to-dismiss — adjusts the tilt but does not resolve the central debate.